<DOC>
	<DOCNO>NCT01198236</DOCNO>
	<brief_summary>Invasive fungal infection ( IFI ) remain major cause death among neutropenic patient receive chemotherapy leukemia , submit stem cell transplantation . Patients history invasive fungal infection ( IFI ) high risk develop relapse fatal complication . Prompt intensive antifungal therapy , improved response survival , allow increase antifungal treatment , include secondary antifungal prophylaxis . Few study address role previous IFI feasibility stem cell transplant , secondary prophylaxis antifungal drug prevent recurrence infection transplantation . However , give lack prospective study , role secondary antifungal prophylaxis remain unclear . Itraconazole wide-spectrum triazole antifungal agent active Candida albicans , non-albicans , Aspergillus spp. , Blastomyces dermatitidis , Blastomyces coccidioides , Cryptococcus neoformans , Sporothrix schenkii , Paracoccidioides brasiliensis , Histoplasma spp . various kind yeast fungi mycetes . The role itraconazole IFI prophylaxis treatment prove many interventional study . In prospective , multicentric study secondary prophylaxis , itraconazole give standard dose patient undergo allogeneic stem cell transplantation chemotherapy prior invasive fungal infection , assess efficacy safety itraconazole secondary prophylaxis .</brief_summary>
	<brief_title>Efficacy Itraconazole Secondary Prophylaxis Patients Undergoing Allogeneic Stem Cell Transplantation Chemotherapy With Prior Invasive Fungal Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Man woman 18 65 year age , inclusive . Patients affect hematological malignancy , receive chemotherapy , submit stem cell transplantation . Patients previous proven probable invasive fungal infection , residual absent lesion CT scan Xray absence clinical sign fungal infection time enrollment . Or , possible IFI patient without microbiological evidence effective antifungal therapy history . ( The diagnosis accord definition Chinese guideline diagnosis treatment invasive fungal infection immunocompromised patient cancer cancer hematopoietic stem cell transplant . ) Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . Lack clinical symptom invasive fungal infection Patient response previous intravenous itraconazole antifungal therapy . Currently take contraindicate medication teldane , astemizol , cisapride HMG－CoA reductase inhibitor（e.g . Simvastatin , ovastatin , oral Midazolam Triazolam） History allergy intolerance imidazole azoles antifungal agents（e.g . Fluconazol , Itraconazole , Ketoconazole , Miconazole , Clotrimazole） Pregnant woman , lactate woman woman child bear potential without apply valid contraceptive measure Patients current cardiac dysfunction ( especially congestive heart failure ) history congestive heart failure Patients severe liver dysfunction ( aminotransferase level ≥5 time upper limit normal total bilirubin level ≥3mg/dL ( 51.3 μmol/L ) ; severity liver dysfunction match criterion patient bad condition suitable trial ( doctor make decision ) ; Patients renal insufficiency serum Ccr level &lt; 30ml/min , calculate follow formula : Male : Ccr ( ml/min ) = ( 140age ) ×weight ( kg ) / ( 0.8136×Crea ( μmol/L ) ) Female : Ccr ( ml/min ) = ( 140age ) ×weight ( kg ) ×0.85/ ( 0.8136× Crea ( μmol/L ) ) Patients receive experimental drug within 10 day plan start treatment . Patients bad whole body status suitable trial ( doctor make decision )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>hematological malignancy</keyword>
	<keyword>previous proven probable invasive fungal infection</keyword>
</DOC>